These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23643735)

  • 1. Ion-pair strategy for enabling amifostine oral absorption: rat in situ and in vivo experiments.
    Samiei N; Mangas-Sanjuan V; González-Álvarez I; Foroutan M; Shafaati A; Zarghi A; Bermejo M
    Eur J Pharm Sci; 2013 Jul; 49(4):499-504. PubMed ID: 23643735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement and in vitro evaluation of amifostine permeation through artificial membrane (PAMPA) via ion pairing approach and mechanistic selection of its optimal counter ion.
    Samiei N; Shafaati A; Zarghi A; Moghimi HR; Foroutan SM
    Eur J Pharm Sci; 2014 Jan; 51():218-23. PubMed ID: 24161609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intestinal absorption and activation of decitabine amino acid ester prodrugs mediated by peptide transporter PEPT1 and enterocyte enzymes.
    Tao W; Zhao D; Sun M; Wang Z; Lin B; Bao Y; Li Y; He Z; Sun Y; Sun J
    Int J Pharm; 2018 Apr; 541(1-2):64-71. PubMed ID: 29471144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Formulation Strategy to Improve the Feasibility of Amifostine Administration.
    Ranganathan K; Simon E; Lynn J; Snider A; Zhang Y; Nelson N; Donneys A; Rodriguez J; Buchman L; Reyna D; Lipka E; Buchman SR
    Pharm Res; 2018 Mar; 35(5):99. PubMed ID: 29556791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability and newer methods of delivery of phosphorothioate radioprotectors.
    Fleckenstein L; Swynnerton NF; Ludden TM; Mangold DJ
    Pharmacol Ther; 1988; 39(1-3):203-12. PubMed ID: 2849124
    [No Abstract]   [Full Text] [Related]  

  • 6. Characterization of ethiofos absorption in the rat small intestine.
    Geary RS; Swynnerton NF; Timmons SF; Mangold DJ
    Biopharm Drug Dispos; 1991 May; 12(4):261-74. PubMed ID: 1651790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New dosing regimens for amifostine: a pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion.
    Bonner HS; Shaw LM
    J Clin Pharmacol; 2002 Feb; 42(2):166-74. PubMed ID: 11831539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical studies on the radioprotective efficacy and pharmacokinetics of subcutaneously administered amifostine.
    Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):2-8. PubMed ID: 12577236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ion-pair approach coupled with nanoparticle formation to increase bioavailability of a low permeability charged drug.
    Lozoya-Agullo I; Planelles M; Merino-Sanjuán M; Bermejo M; Sarmento B; González-Álvarez I; González-Álvarez M
    Int J Pharm; 2019 Feb; 557():36-42. PubMed ID: 30578978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCM-AMI, a Polyethylene Glycol Micelle with Amifostine, as an Acute Radiation Syndrome Protectant in C57BL/6 Mice.
    Chen CH; Kuo ML; Wang JL; Liao WC; Chang LC; Chan LP; Lin J
    Health Phys; 2015 Sep; 109(3):242-8. PubMed ID: 26222219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing Oral Bioavailability of Cyclic RGD Hexa-peptides by the Lipophilic Prodrug Charge Masking Approach: Redirection of Peptide Intestinal Permeability from a Paracellular to Transcellular Pathway.
    Schumacher-Klinger A; Fanous J; Merzbach S; Weinmüller M; Reichart F; Räder AFB; Gitlin-Domagalska A; Gilon C; Kessler H; Hoffman A
    Mol Pharm; 2018 Aug; 15(8):3468-3477. PubMed ID: 29976060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the intestinal absorption and bioavailability of γ-tocotrienol and α-tocopherol: in vitro, in situ and in vivo studies.
    Abuasal BS; Qosa H; Sylvester PW; Kaddoumi A
    Biopharm Drug Dispos; 2012 Jul; 33(5):246-56. PubMed ID: 22528033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral administration is as effective as intraperitoneal administration of amifostine in decreasing nitroxide EPR signal decay in vivo.
    Elas M; Parasca A; Grdina DJ; Halpern HJ
    Biochim Biophys Acta; 2003 Mar; 1637(2):151-5. PubMed ID: 12633903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility study of the pharmacology of local application of amifostine (WR-2721) to the buccal mucosa in guinea pigs.
    Li C; Wang S; Huang T; Chen N; Ou M
    Pharmacology; 2013; 91(5-6):281-6. PubMed ID: 23736649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of dose and schedule on the efficacy of ethyol: preclinical studies.
    Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):31-9. PubMed ID: 14727238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternate delivery route for amifostine as a radio-/chemo-protecting agent.
    Praetorius NP; Mandal TK
    J Pharm Pharmacol; 2008 Jul; 60(7):809-15. PubMed ID: 18549666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical modeling of improved amifostine (Ethyol) use in radiation therapy.
    Cassatt DR; Fazenbaker CA; Bachy CM; Hanson MS
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):97-102. PubMed ID: 11917293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the potential of ion pair formation to improve the oral absorption of two potent antiviral compounds, AMD3100 and PMPA.
    Van Gelder J; Witvrouw M; Pannecouque C; Henson G; Bridger G; Naesens L; De Clercq E; Annaert P; Shafiee M; Van den Mooter G; Kinget R; Augustijns P
    Int J Pharm; 1999 Sep; 186(2):127-36. PubMed ID: 10486430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and evaluation of biodegradable enteric microcapsules of amifostine for oral delivery.
    A G; Ren L; Zhou Z; Lu D; Wang S
    Int J Pharm; 2013 Sep; 453(2):441-7. PubMed ID: 23796837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue.
    Gupta D; Varghese Gupta S; Dahan A; Tsume Y; Hilfinger J; Lee KD; Amidon GL
    Mol Pharm; 2013 Feb; 10(2):512-22. PubMed ID: 23244438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.